Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Dexamethasone; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2016 Preliminary results (n=24) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 28 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.